In this study, we explored the intricate interplay between intraoperative radiation therapy (IORT) and the immune landscape of the tumor microenvironment (TME) in patients with hormone receptor-positive/HER2-negative early-stage invasive breast carcinoma, a traditionally considered immune-desert or “cold” tumor (24). This evidence concerns the gene NR4A1 and invasive breast carcinoma.